A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning Using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder in Treatment-Naive Children and Adolescents
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Atomoxetine (Primary) ; Methylphenidate; Reboxetine
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms ADHD-LIFE
- Sponsors Eli Lilly and Company
- 29 Jun 2012 Additional trial location added as reported by European Clinical Trials Database.
- 01 Sep 2010 Results of an analysis of the secondary endpoint analysis of the WFRIS score presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology
- 01 Sep 2010 Other early standard therapy identified as methylphenidate or reboxetine, and descriptors added